TTRX Turn Therapeutics Inc.
Price Chart
Executive Summary
Turn Therapeutics reported positive interim Phase 2 data for GX-03 in moderate-to-severe atopic dermatitis, showing rapid and deep efficacy responses (92.6% EASI-50, 70.4% EASI-75, 44.4% EASI-90 at week 4) with no safety concerns. The company is optimizing the trial and preparing FDA interactions, presenting at Jefferies on June 4. This is a significant derisking catalyst for the candidate.
Actionable Insight
The strong interim efficacy and safety data de-risk GX-03 in atopic dermatitis. Watch for the Jefferies presentation on June 4 and any FDA meeting announcements for further upside. The high vehicle response rate (65% EASI-50) is a caution, but GX-03 showed incremental depth improvement.
Key Facts
- 92.6% of GX-03-treated subjects achieved EASI-50 at week 4 vs 65.2% for vehicle
- 70.4% achieved EASI-75 at week 4
- 44.4% achieved EASI-90 at week 4 vs 30.4% for vehicle
- 51.9% achieved EASI-90 at week 8 vs 34.8% for vehicle
- No treatment-related serious adverse events, tolerability issues, or discontinuations
- Interim analysis informed trial optimization; enrollment nearing completion
- Company preparing FDA interactions; data to be presented at Jefferies Global Healthcare conference on June 4, 2026
Financial Impact
Not specified
Risk Factors
- High placebo/vehicle response may dilute treatment effect in later-stage trials
- Small sample size (50 subjects) limits statistical reliability
- Clinical-stage company with no revenue; financing risk remains
- Regulatory pathway uncertain; FDA interactions pending
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-063177 |
| Document: ea029288001ex99-1.htm | 0001213900-26-063177 |
| Document: 0001213900-26-063177-index-headers.html | 0001213900-26-063177 |
| Document: 0001213900-26-063177-index.html | 0001213900-26-063177 |
| Document: 0001213900-26-063177.txt | 0001213900-26-063177 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 3, 2026
11d ago
|
8-K
| $6.02 $5.75 | ▼ −4.57% | ▼ −4.97% | $6.05 (+0.42%) |
|
Jun 1, 2026
13d ago
|
8-K
| $6.33 $6.42 | ▲ +1.42% | ▲ +1.28% | $6.05 (−4.50%) |
|
May 27, 2026
18d ago
|
8-K
| $5.29 $5.31 | ▲ +0.38% | ▼ −0.17% | $6.05 (+14.27%) |
|
May 19, 2026
26d ago
|
8-K
| $4.55 $4.76 | ▲ +4.62% | ▲ +3.58% | $6.05 (+32.86%) |
|
May 18, 2026
27d ago
|
8-K
| $4.90 $4.55 | ▼ −7.14% | ▼ −6.49% | $6.05 (+23.37%) |
|
May 11, 2026
4w ago
|
8-K
| $3.98 $3.98 | · 0.00% | ▼ −0.54% | $6.05 (+51.88%) |
|
Apr 3, 2026
10w ago
|
EFFECT
| $3.33 $3.36 | ▼ −0.90% | ▼ −0.84% | $6.05 (−81.53%) |
|
Mar 31, 2026
10w ago
|
8-K
| $3.12 $3.35 | ▲ +7.54% | ▲ +7.46% | $6.05 (+94.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access